An Evidence Based Guideline For Diabetes Mellitus For Primary Care

Abstract

Diabetes mellitus (DM) is a progressive disorder which is defined as the deficiency in insulin secretion and abnormal glucose metabolism and is caused by metabolic incompatibilities. DM is one of the most commonly encountered diseases in primary care, according to the high prevalence rates (% 7).

Diabetes mellitus (DM) is a progressive disorder which is defined as the deficiency in insulin secretion and abnormal glucose metabolism and is caused by metabolic incompatibilities. DM is one of the most commonly encountered diseases in primary care, according to the high prevalence rates (% 7).

Keywords

• Diabetes Mellitus
• Primary Care
• Guideline

Diabetes Mellitus İçin Birinci Basamak Kullanımına Yönelik Kanıta Dayalı Bir Rehber Çalışması

Öz

Diabetes Mellitus (DM); insülin sekresyon defekti ve anormal glukoz metabolizması ile tanımlanan, metabolik bozuklukların yol açtığı ilerleyici bir hastalıktır. Yüksek prevalansı (% 7) nedeniyle birinci basamakta en sık karşılaşılan hastalıklardandır. DM, insülin hormon sekresyonunun ve/veya insüline karşı doku cevabının mutlak veya göreceli azlığı sonucu karbonhidrat, protein ve yağ metabolizmasında bozukluklara yol açan kronik hiperglisemik bir grup metabolizma hastalığıdır . American Diabetes Association (ADA) ‘ya göre, Tip 1, Tip 2, gestasyonel ve diğer spesifik tipler olarak sınıflandırılmaktadır. Tip 1 DM de mutlak insülin eksikliği varken, Tip 2 DM de insülin rezistansı ve rölatif bir insülin eksikliği vardır.1, , Diyabetik popülasyonun %10-20’si Tip 1 DM, %80-90’nı ise Tip 2 DM’dir. 

Anahtar Kelimeler

• Diabetes Mellitus
• Birinci basamak
• Rehber

Kaynakça

1. 1. Standards of medical care in diabetes. American Diabetes Association. Diabetes Care. 2011. http://care.diabetesjournals.org/ content/34/Supplement_1/S11.full
2. 2. Banerji M,Lebovitz H:Insulin sensitive and insulin resistant variants in IDDM.Diabetes,1989; 38:784-792.
3. 3. Turner RC,Holman RR,Matthews D. et al.:Insulin deficiency and insulin resistance interaction in diabetes :estimation of their relatives contribution by feedback analysis from basal plasma insulin and glucose concentrations. Metabolism 1979;28:1086- 1096.
4. 4. Diagnosis and Classification of Diabetes Mellitus, Diabetes Care January 2009 vol. 32 no. Supplement 1 S62-S67.
5. 5. Baekkeskov S,Neilsen JH,Marner B,Bilde T,Ludvigsson J,Lernmark A:Autoantibodies in newly diagnosed diabetic children with immunoprecipitate human pancreatic islet cell proteins.Nature1982; 298:167-169.
6. 6. Myers MA,Rabin DU,RowleyMJ:Pancreatic islet cell cytoplasmic antibody in diabetes is represented by antibodies to isletcell antigen 512 and glutamic asid decarboxylase.Diabetes ,1995:44:1290-1295
7. 7. Atkinson MA,Maclaren NK:The pathogenesis of insülin dependent diabetes.N. Englend.J.Med. 1994:331:1428-1436.
8. 8. Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344:1343-1348.

9. 9. Holman RR, Paul SK, Bethel MA,et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577-1589.
10. 10. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes:A consensus algorithm for the initiation and adjustment of therapy: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32:193- 199.
11. 11. Rotella CM, Monami M, Mannucci E. Metformin beyond diabetes:new life for an old drug. Curr Diabetes Rev 2006;2: 307-315,
12. 12. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional tteatment and risk of complications in patients with type 2 diabetes, Lancet 1998;352:837-853.
13. 13. Lebovitz HE. Therapy for diabetes mellitus and related disorders. 4. Ed. Virginia, Port City Press, 2004;192-197.
14. 14. Staels B, Fruchart JC. Therapeutic roles of peroxisome proliferator-activated receptor agonists. Diabetes 2005;54:2460-2470.
15. 15. Gromada J, Rorsman P. Horm Metab Res. 2004;36:822–829.
16. 16. DeFronzo R.A, Ratner E R, Han J, et al..Effects of exenatide on glycemic control and weight over 30 weeks in metformine treated patients with type 2 diabetes. Diabetes care .2005;28:1092- 1100.
17. 17. Cushman WC, Evans GW, et al. Effects of intensive bloodpressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362:1575-1585.